Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30153250 | 1.00 | ALDH1A1 (0.48) | ALDH1A1L3MBTL1SMN1; SMN2CYP1A2TSHR | |
| SCHEMBL8894967 | 0.87 | VCAM1 (0.51) | ALDH1A1L3MBTL1SMN1; SMN2CYP1A2TSHR | |
| SCHEMBL31401320 | 0.83 | CDC25B (0.45) | SMN1; SMN2TSHRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8896458 | 0.82 | VCAM1 (0.49) | ALDH1A1L3MBTL1SMN1; SMN2CYP1A2TSHR | |
| SCHEMBL8896076 | 0.81 | VCAM1 (0.48) | ALDH1A1L3MBTL1SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL15778276 | 0.79 | SLC6A3 (0.53) | ALDH1A1L3MBTL1SMN1; SMN2CYP1A2TSHR | |
| SCHEMBL16893324 | 0.78 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1SMN1; SMN2CYP1A2TSHR | |
| SCHEMBL7818115 | 0.78 | CHRNB2 (0.44) | ALDH1A1L3MBTL1SMN1; SMN2CYP1A2TSHR | |
| SCHEMBL31587402 | 0.77 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1SMN1; SMN2CYP1A2TSHR | |
| SCHEMBL669263 | 0.77 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1SMN1; SMN2CYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485169-B2 | Compounds | Grey Wolf Therapeutics Limited (GB) | 2025-12-02 | — | — | US | disclosed |
| US-12377084-B2 | ERAP1 modulators | Grey Wolf Therapeutics Limited (GB) | 2025-08-05 | — | — | US | disclosed |
| US-20240376046-A1 | PHENYL-SULFAMOYL-BENZOIC ACID DERIVATIVES AS ERAP1- MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2024-11-14 | — | — | US | disclosed |
| US-20240366595-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2024-11-07 | — | — | US | disclosed |
| US-12023333-B2 | Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators | Grey Wolf Therapeutics Limited (GB) | 2024-07-02 | — | — | US | disclosed |
| EP-4376955-A1 | PHENYL-SULFAMOYL-BENZOIC ACID DERIVATIVES AS ERAP1- MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2024-06-05 | — | — | EP | disclosed |
| CN-117881657-A | Phenyl-sulfamoyl-benzoic acid derivatives as ERAP1 modulators | 格雷沃尔夫治疗有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20230064417-A1 | COMPOUNDS | Grey Wolf Therapeutics Limited (GB) | 2023-03-02 | — | — | US | disclosed |
| WO-2023007188-A1 | PHENYL-SULFAMOYL-BENZOIC ACID DERIVATIVES AS ERAP1- MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023007188-A1 | PHENYL-SULFAMOYL-BENZOIC ACID DERIVATIVES AS ERAP1- MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2023-02-02 | — | — | WO | disclosed |
| US-20230000851-A1 | ERAP1 MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2023-01-05 | — | — | US | disclosed |
| US-20220347176-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2022-11-03 | — | — | US | disclosed |
| EP-4058429-A1 | ERAP1 MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2022-09-21 | — | — | EP | disclosed |
| EP-3966196-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2022-03-16 | — | — | EP | disclosed |
| EP-3883650-A1 | COMPOUNDS | Grey Wolf Therapeutics Limited (GB) | 2021-09-29 | — | — | EP | disclosed |
| CN-113056305-A | Compound (I) | 格雷沃尔夫治疗有限公司 | 2021-06-29 | — | — | CN | disclosed |
| WO-2021094763-A1 | ERAP1 MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2021-05-20 | — | — | WO | disclosed |
| WO-2020225569-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366595-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | CHP1, ERAP1, QSOX1 | ALDH1A1 1477/4885L3MBTL1 3192/4885SMN1; SMN2 4417/4885 |
| US-20220347176-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | ERAP1, CHP1, QSOX1 | ALDH1A1 1546/4885L3MBTL1 1197/4885SMN1; SMN2 4305/4885 |
| US-12377084-B2 | ERAP1 modulators | ERAP1, NR1I3, HRH4 | ALDH1A1 2660/4885L3MBTL1 4128/4885SMN1; SMN2 4606/4885 |
| US-20230064417-A1 | COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH4, CBR3 | ALDH1A1 2613/4885L3MBTL1 3697/4885SMN1; SMN2 3059/4885 |
| US-12023333-B2 | Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators | ERAP1, CHP1, QSOX1 | ALDH1A1 1431/4885L3MBTL1 2457/4885SMN1; SMN2 4365/4885 |
| US-20230000851-A1 | ERAP1 MODULATORS | ERAP1, NR1I3, HRH4 | ALDH1A1 2660/4885L3MBTL1 4128/4885SMN1; SMN2 4606/4885 |
| US-12485169-B2 | Compounds | SLC10A1, VHL, CFTR | ALDH1A1 276/4885L3MBTL1 4696/4885SMN1; SMN2 378/4885 |
| US-20240376046-A1 | PHENYL-SULFAMOYL-BENZOIC ACID DERIVATIVES AS ERAP1- MODULATORS | ERAP1, XPO1, RRP15 | ALDH1A1 2435/4885L3MBTL1 3137/4885SMN1; SMN2 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.